ストックスクリーナーアプリを入手
23.90
0.58%
-0.14
アフターアワーズ：
23.90
前日終値:
$24.04
開ける：
$24.08
24時間の取引高:
1.86M
Relative Volume:
0.95
時価総額：
$2.13B
収益：
$333.87M
当期純損益:
$-169.00M
株価収益率:
-11.72
EPS:
-2.04
ネットキャッシュフロー:
$-157.30M
1週間 パフォーマンス:
-1.36%
1か月 パフォーマンス:
+36.57%
6か月 パフォーマンス:
+33.37%
1年 パフォーマンス:
+70.84%
1日の値動き範囲:
$23.61
$24.39
1週間の範囲:
$22.05
$25.48
52週間の値動き範囲:
$12.91
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
23.90 | 2.14B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
How to use a screener to detect Travere Therapeutics Inc. breakoutsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Weekly Trade Analysis & Proven Capital Preservation Tips - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitorsPortfolio Value Summary & Weekly Watchlist of Top Performers - newser.com
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Is GAIL India Limited One of the Top Picks for Growth Investors in YEARFlag and Pennant Patterns & Free Phenomenal Trading Returns - earlytimes.in
Published on: 2025-09-28 13:45:23 - earlytimes.in
Published on: 2025-09-28 02:30:57 - newser.com
Travere Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Double Digit Returns - earlytimes.in
Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Sharecast News
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 10,000 Shares of Stock - MarketBeat
Travere Therapeutics' (TVTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Wall Street Zen Downgrades Travere Therapeutics (NASDAQ:TVTX) to Hold - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to “Hold” - Defense World
Travere Therapeutics (TVTX): Evaluating Valuation After FDA Fast-Track and Positive FILSPARI Study Results - Sahm
Travere Therapeutics (NASDAQ:TVTX) Earns Buy Rating from HC Wainwright - Defense World
Travere Therapeutics Inc. stock momentum explainedJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Sector ETF performance correlation with Travere Therapeutics Inc.July 2025 Technicals & Community Supported Trade Ideas - newser.com
MACD Signal: How sensitive is Travere Therapeutics Inc. to inflation2025 Winners & Losers & Free Reliable Trade Execution Plans - خودرو بانک
HC Wainwright & Co. Reiterates Buy Rating for Travere Therapeuti - GuruFocus
Trading Action: Does Travere Therapeutics Inc. stock have upside surprise potential2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
Whale Trades: Can Travere Therapeutics Inc. be the next market leaderWeekly Gains Report & Risk Managed Investment Signals - خودرو بانک
Nephrotic Syndrome Market Analysis: Epidemiology Insights, Therapies, Companies, DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers - Barchart.com
Can Travere Therapeutics Inc be the next market leaderQuarterly Growth Report & Breakout Confirmation Alerts - khodrobank.com
Travere Therapeutics Inc. stock outlook for YEARPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
Stifel Nicolaus Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $25.00 - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $35.00 Price Target at Wells Fargo & Company - MarketBeat
Live market analysis of Travere Therapeutics Inc.Weekly Risk Report & Community Consensus Picks - newser.com
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - MSN
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Woodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results - Sahm
Signal Recap: Whats the analyst consensus on Travere Therapeutics IncExit Point & Safe Entry Zone Identification - خودرو بانک
Quarterly Recap: Is Travere Therapeutics Inc.’s growth already priced in2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Highs Report: Is Travere Therapeutics Inc subject to activist investor interestDay Trade & Free Long-Term Investment Growth Plans - خودرو بانک
Institution Moves: What is Travere Therapeutics Incs debt to equity ratioGDP Growth & Stock Market Timing Techniques - خودرو بانک
Aug Highlights: How liquid is Travere Therapeutics Inc stockJuly 2025 Price Swings & Stock Market Timing Techniques - خودرو بانک
Short Covering: Is Cuprina Holdings Cayman Limited a turnaround storyTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - MSN
Travere Therapeutics (TVTX) Is Up 8.5% After FDA Removes Advisory Panel Step for FILSPARI in FSGS - Sahm
Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.8%Should You Sell? - MarketBeat
Travere Therapeutics Sees Unusually Large Options Volume (NASDAQ:TVTX) - MarketBeat
Polar Asset Management Partners Inc. Invests $304,000 in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX) - Seeking Alpha
TVTX: Stifel Raises Price Target to $25, Maintains Hold Rating | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):